These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 1101714)
41. A Descriptive Study on the Neonatal Morbidity Profile of Autism Spectrum Disorders, Including a Comparison with Other Neurodevelopmental Disorders. Atladóttir HÓ; Schendel DE; Parner ET; Henriksen TB J Autism Dev Disord; 2015 Aug; 45(8):2429-42. PubMed ID: 25758820 [TBL] [Abstract][Full Text] [Related]
43. Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. Kaufmann R; Goldberg-Stern H; Shuper A J Child Neurol; 2009 Jun; 24(6):727-33. PubMed ID: 19491115 [TBL] [Abstract][Full Text] [Related]
44. The role of methylphenidate and dextroamphetamine in hyperactivity in children. Solomons G J Iowa Med Soc; 1971 Nov; 61(11):658-61. PubMed ID: 4107192 [No Abstract] [Full Text] [Related]
45. Health care use and health and functional impact of developmental disabilities among US children, 1997-2005. Boulet SL; Boyle CA; Schieve LA Arch Pediatr Adolesc Med; 2009 Jan; 163(1):19-26. PubMed ID: 19124699 [TBL] [Abstract][Full Text] [Related]
46. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. Millichap JG Pediatrics; 1978 Jan; 61(1):146-7. PubMed ID: 263851 [No Abstract] [Full Text] [Related]
47. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Elia J; Borcherding BG; Rapoport JL; Keysor CS Psychiatry Res; 1991 Feb; 36(2):141-55. PubMed ID: 2017529 [TBL] [Abstract][Full Text] [Related]
48. Magnesium pemoline and dextroamphetamine: a controlled study in children with minimal brain dysfunction. Conners CK; Taylor E; Meo G; Kurtz MA; Fournier M Psychopharmacologia; 1972; 26(4):321-36. PubMed ID: 4508756 [No Abstract] [Full Text] [Related]
49. Pemoline (Cylert) for minimal brain dysfunction. Med Lett Drugs Ther; 1976 Jan; 18(2):5-6. PubMed ID: 1107790 [No Abstract] [Full Text] [Related]
50. Midline spike discharges: clinical and EEG correlates. Pourmand RA; Markand ON; Thomas C Clin Electroencephalogr; 1984 Oct; 15(4):232-6. PubMed ID: 6518659 [TBL] [Abstract][Full Text] [Related]
52. [Children with high potential and difficulties: Contributions of clinical research]. Tordjman S; Vaivre-Douret L; Chokron S; Kermarrec S Encephale; 2018 Nov; 44(5):446-456. PubMed ID: 30340779 [TBL] [Abstract][Full Text] [Related]
53. Treatment of attention-deficit/hyperactivity disorder. Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990 [TBL] [Abstract][Full Text] [Related]
54. The school health team and school health physician: new role and operation. Kappelman M; Roberts P; Rinaldi R; Cornblath M Am J Dis Child; 1975 Feb; 129(2):191-5. PubMed ID: 1119456 [TBL] [Abstract][Full Text] [Related]
55. Using cerebral stimulants to treat minimal brain dysfunction. Loney J; Ordoña TT Am J Orthopsychiatry; 1975 Jul; 45(4):564-572. PubMed ID: 1180339 [TBL] [Abstract][Full Text] [Related]
56. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. Lurie S; O'Quinn A J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171 [TBL] [Abstract][Full Text] [Related]
57. Letter: Universal periodic developmental assessment. Mac Keith R Lancet; 1975 Feb; 1(7902):328. PubMed ID: 46463 [No Abstract] [Full Text] [Related]